Unity Biotechnology, Inc. (UBX)

1.6236 +0.0136 (+0.84%) 市場開市。 截至 02:12PM EDT。

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080
United States
650 416 1192
https://unitybiotechnology.com

版塊: Healthcare
行業: Biotechnology
全職員工: 19

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Anirvan Ghosh Ph.D.	CEO & Director	940.4k	無	1964
Dr. Nathaniel E. David A.B., Ph.D.	Co-Founder & Executive Director	40k	無	1968
Ms. Lynne Marie Sullivan	CFO & Head of Corporate Development	663.63k	無	1966
Mr. Alexander Hieu Nguyen J.D.	Chief Legal Officer, Head of Operations & Corporate Secretary	589.4k	無	1977
Dr. Jan M. van Deursen	Founder	無	無	無
Dr. Judith Campisi Ph.D.	Founder	無	無	無
Mr. Daohong Zhou M.D.	Founder	無	無	無
Dr. Przemyslaw Sapieha Ph.D.	Chief Scientist	無	無	無
Ms. Sharon Klier M.D., M.P.H.	Head of Ophthalmology & Chief Development Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

公司管治

截至 2024年5月1日 止，Unity Biotechnology, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：9；董事會：9；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。